Toxina botulínica tipo a: experiencia con 2.000 aplicaciones

Autores:: Hemández, Leonardo Fabio
Palacios, Eduardo

Tipo de recurso:: Article of journal

Fecha de publicación:: 2012

Institución:: Fundación Universitaria de Ciencias de la Salud - FUCS

Repositorio:: Repositorio Digital Institucional ReDi

Idioma:: spa

id	FUCS2_92ac009e9e361ef4908d1dd845a9d2d7
oai_identifier_str	oai:repositorio.fucsalud.edu.co:001/2854
network_acronym_str	FUCS2
network_name_str	Repositorio Digital Institucional ReDi
repository_id_str
dc.title.spa.fl_str_mv	Toxina botulínica tipo a: experiencia con 2.000 aplicaciones
dc.title.translated.eng.fl_str_mv	Botulinum toxin type a: an experience with 2.000 injections
title	Toxina botulínica tipo a: experiencia con 2.000 aplicaciones
spellingShingle	Toxina botulínica tipo a: experiencia con 2.000 aplicaciones toxina botulínica espasmo hemifacial blefaroespasmo distonía espasticidad cefalea crónica botulinum toxin hemifacial spasm blepharospasm dystonia spasticity chronic migraine
title_short	Toxina botulínica tipo a: experiencia con 2.000 aplicaciones
title_full	Toxina botulínica tipo a: experiencia con 2.000 aplicaciones
title_fullStr	Toxina botulínica tipo a: experiencia con 2.000 aplicaciones
title_full_unstemmed	Toxina botulínica tipo a: experiencia con 2.000 aplicaciones
title_sort	Toxina botulínica tipo a: experiencia con 2.000 aplicaciones
dc.creator.fl_str_mv	Hemández, Leonardo Fabio Palacios, Eduardo
dc.contributor.author.spa.fl_str_mv	Hemández, Leonardo Fabio Palacios, Eduardo
dc.subject.spa.fl_str_mv	toxina botulínica espasmo hemifacial blefaroespasmo distonía espasticidad cefalea crónica
topic	toxina botulínica espasmo hemifacial blefaroespasmo distonía espasticidad cefalea crónica botulinum toxin hemifacial spasm blepharospasm dystonia spasticity chronic migraine
dc.subject.eng.fl_str_mv	botulinum toxin hemifacial spasm blepharospasm dystonia spasticity chronic migraine
publishDate	2012
dc.date.accessioned.none.fl_str_mv	2012-12-01 00:00:00 2022-06-29T19:37:11Z
dc.date.issued.none.fl_str_mv	2012-12-01
dc.date.available.none.fl_str_mv	2012-12-01 00:00:00 2022-06-29T19:37:11Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.eng.fl_str_mv	Journal article
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ART
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.doi.none.fl_str_mv	10.31260/RepertMedCir.v21.n4.2012.834
dc.identifier.issn.none.fl_str_mv	0121-7372
dc.identifier.uri.none.fl_str_mv	https://repositorio.fucsalud.edu.co/handle/001/2854
dc.identifier.eissn.none.fl_str_mv	2462-991X
dc.identifier.url.none.fl_str_mv	https://doi.org/10.31260/RepertMedCir.v21.n4.2012.834
identifier_str_mv	10.31260/RepertMedCir.v21.n4.2012.834 0121-7372 2462-991X
url	https://repositorio.fucsalud.edu.co/handle/001/2854 https://doi.org/10.31260/RepertMedCir.v21.n4.2012.834
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Schaffner W. Clostridium botulinum. In: Mandell GL, Bennett JE, Dolin R, edi tors. Douglas & Bennett's Principies and Practice of Jnfectious Diseases. 3rd. ed. New York: Churchill Livingstone; 1990. p. 1847-S0. 2. Botulismo. En: Eulenburg A. Diccionario enciclopédico de medicina y cirugía prácticas. Madrid: Agustín Jubera editor; 1886. p. 113-9. 3. Bulloch W. History. En: Medica! Research Council. A System of Bacteriology in Relation to Medicine. London: His Majesty's Statíonery Office;l929. p. 373-4. 4. Hatheway CL. Clostridium botulinum. In: Gorbach SL, Bartlett JG, BlackJow NR. Jnfectious Diseases. Philadelphía: WB Saunders; 1992. p. 1583- 7. 5. Hallett M, Glocker F, DeuschJ G. Mechanism of action of botulinum toxin. Ann Neurol. 1994; 36:449-50. 6. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other micro bial neurotoxins in medicine. Microbio! Rev. 1992; 56: 80-99. 7. Bressman SB. Dystonia genotypes, phenotypes and classification. Adv neurol. 2004; 94: 101-7. 8. MDVU. MD Virtual university. Adult dosing guidelines. In: Management of dys tonia with Borulinum Toxin Type A (Botox). Edition 2.0. Revised, August 2005. 9. Odderson IR. Botulinum toxin injection guide. New York: Demos Medica! Pub lishing; 2008. 10. Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992; 15(9):1045-9. 11. Brin MF, Fahn S, Moskowitz C, et al. (1987). Localized injections of botuli num toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987; 2 : 237 54. 12. Berardelli A, Rothwell JC, Day BL, Marsden CD. Pathophysiology of blepharo spasm and oromandibular dystonia. Brain. 1985; 108(Pt 3): 593-608. 13. Berardelli A, Rothwell JC, Hallett M, et al. The pathopbysiology of primary dys tonia. Brain. 1998; 121 (Pt 7): 1195-212. 14. Marsden CD. Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psy chiatry. 1976; 39: 1204-9. 15. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006; 5: 864-72. 16. Campos EC, Bolzani R, Schiavi C, et al. Effect of injection sites of Botulinum toxin for blepbarospasm treatment: statistical analysis. Neuro-ophtlzalmol 1999; 22:17-23. 17. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double blind, placebocontrolled study. Neurology. 1987; 37: 616-23. 18. Toro J, Yepes M, Palacios E. Neurología. 2da ed. Bogotá: Manual Moderno; 2010. p. 479-80. 19. Foltz EL, Knopp LM, Ward AA. Experimental spasmodic torticollis. J Neuro surg. 1959; 16: 55 72. 20. Van Zandijcke M. Cervical dystonia (spasmodic torticollis). Sorne aspecls of the natural bistory. Acta Neurol Belg. 1995; 95(4): 210-15. 21. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurology. 1999; 246: 265 74. 22. Truong D, Dubinski R, Hermanowicz N, et al. Posttraumatic torticollis. Arch Neurol. 1991; 48: 221-3. 23. Truong D, Lewitt, P, Cullis, P. Effects of different injection techniques in the treatment of torticollis with botulinumtoxin. Neurology. 1989; 39 (Suppl): 294. 24. Anderson TJ, Rivest J, Stell R, et al. Botulinumtoxin treatment of spasmodic torticollis. J R Soc Med. 1992; 85: 524-9. 25. Poewe W, Schelosky L, Kleedorfer B, et al. (1992). Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in thirty seven patients. J Neurol. 1992; 239: 21-5. 26. Lance JW. Disordered muscle tone and movement. Clin Exp Neurol. 1981; 18: 27-35. 27. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002; 347: 395-400. 28. Childers MK, Brasbear A, Jozefczyk P, el al. Dose-dependent response to in tramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004; 85: 1063-9. 29. Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil. 2005; 27: 176-84. 30. Chin TY, Nattrass GR, Selber P, Graham HK. Accuracy of intramuscular injec tion of botulinum toxin A in juvenile cerebral palsy: a comparison between ma nual needle placement and placement guided by electrical stimulation. J Pediatr Orthop. 2005; 25: 286-91. 31. Hyman N, Barnes M, Bbakta B, el al. Botulinum toxin (Dysport) treatment of bip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000; 68: 707-12. 32. Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dys function. In Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, managemenl and the role of botulinum toxin. New York: WE MOVE; 2002. p. 16-26. 33. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. lmpact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry; 2000; 69: 217-21. 34. Brashear A, McAfee AL, Kuhn ER, Fyffe J. (2004). Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled tria!. Arch Phys Med Rehabil. 2004; 85: 705 9. 35. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. Treatment with botulinum toxin type B for upper limb spasticity. Arch Phys Med Rehabil. 2003; 84: 103-7. 36. MDVU. We Move. Guidelines. Edition 1.0. Botulinum Toxin Type B (Myob loc). Bronx: We Move; 2012. [citado 24 Sep. 2012]. Disponible en: http://www. mdvu.org/ 37. Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lance!. 2004; 363(9421): 1619-31. 38. Palisano RJ, Rosenbaum P, Walter S, et al. (1997). Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997; 45: 113-20. 39. Russman BS, Tilton AH, Gorrnley ME, Jr. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management, and the Role of Botulinum Toxin. New York: WE MOVE; 2002. pp. 134-43. 40. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botuli num toxins. Headacbe. 2003; 43 (Suppl 1): Sl6-24. 41. Welcb M, Purkiss J, Foster K. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000; 38: 245-58. 42. Durham P, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine the rapy. Headache. 2004; 44: 35-43. 43. Cui M, Khanijou S, Rubino J, Aoki R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-33. 44. Tatji J, Uddman R, Edvinsson L. Neuropeptide localization in the 'migraine ge nerator' region of the human brainstem. Cephalalgia. 2001; 21: 96-101. 45. Mathew MT, Frishberg M, Gawel M, et al. Botox CDH study group. Headache 2005; 45:293-307. 46. Blumenfeld A, Binder W, Silberstein SD, Blitzer A. Procedures for Adrniniste ring botulinum toxin type A for migraine and tension-type headache. Headache. 2003; 43:884-91. 47. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventative treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000; 40:445-50. 48. Mauskop, A. The use of botulinum toxin in the treatment of headaches. Pain Physician. 2004; 7: 377 87. 49. Agencia de Evaluacion de Tecnología e investigación Médicas de Cataluña. Guía de práctica clínica del ictus. 2 ed. Barcelona: AATRM; 2007. 50. García-Alfonso F, Guallar E, Bakke OM, Carné X. El placebo en ensayos clíni cos con medicamentos. Med Clin (Barc). 1997; 109: 797-801. 51. Ramos JMJ. Efecto placebo y dolor: bases cerebrales. Neurología. 2007; 22: 99- 105. 52. Lahuerta J, Gutiérrez-Rivas E, Frías J, Gracia D, Dal-Ré R. Controversias éticas sobre la utilización de placebo como tratamiento control en los ensayos clínicos en neurología. Neurología. 2007; 22: 106-13.
dc.relation.bitstream.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/834/868
dc.relation.citationedition.spa.fl_str_mv	Núm. 4 , Año 2012 : Octubre – Diciembre
dc.relation.citationendpage.none.fl_str_mv	306
dc.relation.citationissue.spa.fl_str_mv	4
dc.relation.citationstartpage.none.fl_str_mv	298
dc.relation.citationvolume.spa.fl_str_mv	21
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Repertorio de Medicina y Cirugía
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.source.spa.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/834
institution	Fundación Universitaria de Ciencias de la Salud - FUCS
bitstream.url.fl_str_mv	https://repositorio.fucsalud.edu.co/bitstreams/a76784a0-71df-4489-a109-994bfb0180b8/download
bitstream.checksum.fl_str_mv	80dc11ea6764b19bbef3c9e57a77b28e
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud
repository.mail.fl_str_mv	redi@fucsalud.edu.co
_version_	1811575330964504576
spelling	Hemández, Leonardo Fabiobb1e13783f05b0c95fce94518910708e300Palacios, Eduardo3b67da7cca98d6b540a3320bacb6b9125002012-12-01 00:00:002022-06-29T19:37:11Z2012-12-012012-12-01 00:00:002022-06-29T19:37:11ZSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Saludhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/view/834toxina botulínicaespasmo hemifacialblefaroespasmodistoníaespasticidadcefalea crónicabotulinum toxinhemifacial spasmblepharospasmdystoniaspasticitychronic migraineToxina botulínica tipo a: experiencia con 2.000 aplicacionesBotulinum toxin type a: an experience with 2.000 injectionsapplication/pdfArtículo de revistaJournal articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a8510.31260/RepertMedCir.v21.n4.2012.8340121-7372https://repositorio.fucsalud.edu.co/handle/001/28542462-991Xhttps://doi.org/10.31260/RepertMedCir.v21.n4.2012.834spaSchaffner W. Clostridium botulinum. In: Mandell GL, Bennett JE, Dolin R, edi tors. Douglas & Bennett's Principies and Practice of Jnfectious Diseases. 3rd. ed. New York: Churchill Livingstone; 1990. p. 1847-S0. 2. Botulismo. En: Eulenburg A. Diccionario enciclopédico de medicina y cirugía prácticas. Madrid: Agustín Jubera editor; 1886. p. 113-9. 3. Bulloch W. History. En: Medica! Research Council. A System of Bacteriology in Relation to Medicine. London: His Majesty's Statíonery Office;l929. p. 373-4. 4. Hatheway CL. Clostridium botulinum. In: Gorbach SL, Bartlett JG, BlackJow NR. Jnfectious Diseases. Philadelphía: WB Saunders; 1992. p. 1583- 7. 5. Hallett M, Glocker F, DeuschJ G. Mechanism of action of botulinum toxin. Ann Neurol. 1994; 36:449-50. 6. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other micro bial neurotoxins in medicine. Microbio! Rev. 1992; 56: 80-99. 7. Bressman SB. Dystonia genotypes, phenotypes and classification. Adv neurol. 2004; 94: 101-7. 8. MDVU. MD Virtual university. Adult dosing guidelines. In: Management of dys tonia with Borulinum Toxin Type A (Botox). Edition 2.0. Revised, August 2005. 9. Odderson IR. Botulinum toxin injection guide. New York: Demos Medica! Pub lishing; 2008. 10. Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992; 15(9):1045-9. 11. Brin MF, Fahn S, Moskowitz C, et al. (1987). Localized injections of botuli num toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987; 2 : 237 54. 12. Berardelli A, Rothwell JC, Day BL, Marsden CD. Pathophysiology of blepharo spasm and oromandibular dystonia. Brain. 1985; 108(Pt 3): 593-608. 13. Berardelli A, Rothwell JC, Hallett M, et al. The pathopbysiology of primary dys tonia. Brain. 1998; 121 (Pt 7): 1195-212. 14. Marsden CD. Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psy chiatry. 1976; 39: 1204-9. 15. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006; 5: 864-72. 16. Campos EC, Bolzani R, Schiavi C, et al. Effect of injection sites of Botulinum toxin for blepbarospasm treatment: statistical analysis. Neuro-ophtlzalmol 1999; 22:17-23. 17. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double blind, placebocontrolled study. Neurology. 1987; 37: 616-23. 18. Toro J, Yepes M, Palacios E. Neurología. 2da ed. Bogotá: Manual Moderno; 2010. p. 479-80. 19. Foltz EL, Knopp LM, Ward AA. Experimental spasmodic torticollis. J Neuro surg. 1959; 16: 55 72. 20. Van Zandijcke M. Cervical dystonia (spasmodic torticollis). Sorne aspecls of the natural bistory. Acta Neurol Belg. 1995; 95(4): 210-15. 21. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurology. 1999; 246: 265 74. 22. Truong D, Dubinski R, Hermanowicz N, et al. Posttraumatic torticollis. Arch Neurol. 1991; 48: 221-3. 23. Truong D, Lewitt, P, Cullis, P. Effects of different injection techniques in the treatment of torticollis with botulinumtoxin. Neurology. 1989; 39 (Suppl): 294. 24. Anderson TJ, Rivest J, Stell R, et al. Botulinumtoxin treatment of spasmodic torticollis. J R Soc Med. 1992; 85: 524-9. 25. Poewe W, Schelosky L, Kleedorfer B, et al. (1992). Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in thirty seven patients. J Neurol. 1992; 239: 21-5. 26. Lance JW. Disordered muscle tone and movement. Clin Exp Neurol. 1981; 18: 27-35. 27. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002; 347: 395-400. 28. Childers MK, Brasbear A, Jozefczyk P, el al. Dose-dependent response to in tramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004; 85: 1063-9. 29. Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil. 2005; 27: 176-84. 30. Chin TY, Nattrass GR, Selber P, Graham HK. Accuracy of intramuscular injec tion of botulinum toxin A in juvenile cerebral palsy: a comparison between ma nual needle placement and placement guided by electrical stimulation. J Pediatr Orthop. 2005; 25: 286-91. 31. Hyman N, Barnes M, Bbakta B, el al. Botulinum toxin (Dysport) treatment of bip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000; 68: 707-12. 32. Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dys function. In Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, managemenl and the role of botulinum toxin. New York: WE MOVE; 2002. p. 16-26. 33. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. lmpact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry; 2000; 69: 217-21. 34. Brashear A, McAfee AL, Kuhn ER, Fyffe J. (2004). Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled tria!. Arch Phys Med Rehabil. 2004; 85: 705 9. 35. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. Treatment with botulinum toxin type B for upper limb spasticity. Arch Phys Med Rehabil. 2003; 84: 103-7. 36. MDVU. We Move. Guidelines. Edition 1.0. Botulinum Toxin Type B (Myob loc). Bronx: We Move; 2012. [citado 24 Sep. 2012]. Disponible en: http://www. mdvu.org/ 37. Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lance!. 2004; 363(9421): 1619-31. 38. Palisano RJ, Rosenbaum P, Walter S, et al. (1997). Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997; 45: 113-20. 39. Russman BS, Tilton AH, Gorrnley ME, Jr. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management, and the Role of Botulinum Toxin. New York: WE MOVE; 2002. pp. 134-43. 40. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botuli num toxins. Headacbe. 2003; 43 (Suppl 1): Sl6-24. 41. Welcb M, Purkiss J, Foster K. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000; 38: 245-58. 42. Durham P, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine the rapy. Headache. 2004; 44: 35-43. 43. Cui M, Khanijou S, Rubino J, Aoki R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-33. 44. Tatji J, Uddman R, Edvinsson L. Neuropeptide localization in the 'migraine ge nerator' region of the human brainstem. Cephalalgia. 2001; 21: 96-101. 45. Mathew MT, Frishberg M, Gawel M, et al. Botox CDH study group. Headache 2005; 45:293-307. 46. Blumenfeld A, Binder W, Silberstein SD, Blitzer A. Procedures for Adrniniste ring botulinum toxin type A for migraine and tension-type headache. Headache. 2003; 43:884-91. 47. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventative treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000; 40:445-50. 48. Mauskop, A. The use of botulinum toxin in the treatment of headaches. Pain Physician. 2004; 7: 377 87. 49. Agencia de Evaluacion de Tecnología e investigación Médicas de Cataluña. Guía de práctica clínica del ictus. 2 ed. Barcelona: AATRM; 2007. 50. García-Alfonso F, Guallar E, Bakke OM, Carné X. El placebo en ensayos clíni cos con medicamentos. Med Clin (Barc). 1997; 109: 797-801. 51. Ramos JMJ. Efecto placebo y dolor: bases cerebrales. Neurología. 2007; 22: 99- 105. 52. Lahuerta J, Gutiérrez-Rivas E, Frías J, Gracia D, Dal-Ré R. Controversias éticas sobre la utilización de placebo como tratamiento control en los ensayos clínicos en neurología. Neurología. 2007; 22: 106-13.https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/834/868Núm. 4 , Año 2012 : Octubre – Diciembre306429821Revista Repertorio de Medicina y Cirugíainfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2PublicationOREORE.xmltext/xml2639https://repositorio.fucsalud.edu.co/bitstreams/a76784a0-71df-4489-a109-994bfb0180b8/download80dc11ea6764b19bbef3c9e57a77b28eMD51001/2854oai:repositorio.fucsalud.edu.co:001/28542024-02-02 13:11:15.951https://creativecommons.org/licenses/by-nc-sa/4.0/metadata.onlyhttps://repositorio.fucsalud.edu.coRepositorio Digital de la Fundación Universitaria de Ciencias de la Saludredi@fucsalud.edu.co

Toxina botulínica tipo a: experiencia con 2.000 aplicaciones

Publicaciones similares